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Abstract 
With the introduction of biological agents, over the last two decades treatment prospects in many medical fields 
includingRheumatology have experienced an exciting revolution. The advent of biological therapy for specifically 
rheumatic diseases has provided more effective control of both the underlying disease, and sustained amelioration of 
disease activity, compared to the pre-biological era when only anti-inflammatory and immunosuppressant drugs were 
available. Although the importance of potential improved clinical outcome cannot be overstated, these efficacious 
treatments for rheumatic diseases are not without a high cost.Biological agents are expensive and rheumatological 
diseases are common. The patent and regulatory data protection periods for the first and second waves 
of biological agents based on recombinant proteins have begun to expire, leaving open the potential for development 
and regulatory approval of one or more "generic" versions of these biological therapies, termed "biosimilars" or "BSs" 
in Europe (the term we shall use from henceforth), "subsequent entry biologics" in Canada, or "follow-on-biologics" in 
US. We aimed to review the critical topics of efficacy, safety and regulatory approach of upcoming biosimilars. 
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1. Introduction 
With the introduction of biological agents, over the last two decades treatment prospects in many medical fields 
including Rheumatology have experienced an exciting revolution. For example these drugs have led to a completely 
new approach to the management of patients with inflammatory autoimmune conditions [1]. The advent of biological 
therapy for specifically rheumatic diseases has provided more effective control of both the underlying disease, and 
sustained amelioration of disease activity, compared to the pre-biological era when only anti-inflammatory and 
immunosuppressant drugs were available. Treatment to induce complete remission is now possible. 
Although the importance of potential improved clinical outcome cannot be overstated, these efficacious treatments for 
rheumatic diseases are not without their cost. Biological agents are expensive and rheumatological diseases are 
common. As such even the wealthiest societies are unable to support the indiscriminate widespread use of biological 
agents in all patients requiring biologics [2] and [3]. 
However, the patent and regulatory data protection periods for the first and second waves of biological agents based on 
recombinant proteins have begun to expire, leaving open the potential for development and regulatory approval of one 
or more “generic” versions of these biological therapies, termed “biosimilars” or “BSs” in Europe (the term we shall use 
from henceforth), “subsequent entry biologics” in Canada, or “follow-on-biologics” in US. The development of 
biosimilar therapies could lead to a substantial saving for patients and health systems, and therefore increased 
availability of effective treatment to a wider patient demographic [4]. 
BSs are similar, but crucially not identical to their reference products, because their chemical characteristics are directly 
related to the manufacturing process which cannot be faithfully replicated [5]. Thus, despite the hypothetical promise of 
cheaper drugs compared to the reference biologic that also don't compromise on efficacy, these agents have provoked 
major concerns concerning their short and long term safety-something that must be addressed by regulatory agencies 
before BSs may be approved. Biosimilars of etanercept and rituximab have already been approved in countries such as 
India, China and South Korea [5]; their possible emergence in European and US markets is currently a matter of 
discussion by the European Medicines Agency (EMA) and Food and Drug Administration (FDA) respectively [4]. 
1.1. Definition of biosimilars (BSs) 
Biosimilars are defined as “biological products similar, but not identical, to their already authorized biological reference 
drug”, whereas generic drugs are “precise copies of drugs with the exact same pharmacological effects, side effects, 
risks, safety profile and strength as the reference drug”. Thus, BSs are not generic versions of biological products. 
1.2. Regulatory approval 
Limited documentation is required to obtain this marketing authorization for a conventional small-molecule generic 
drug. In general, to obtain market authorization it is necessary to show pharmaceutical equivalence (i.e. identical active 
substances) and bioequivalence (i.e. comparable pharmacokinetics) between the generic and its reference drug. This can 
often be done in a small study of volunteers, via an abbreviated procedure, and formal clinical efficacy and safety 
studies are not necessary. 
However, this approach cannot be extrapolated to BSs and Biologics. Unlike conventional small-molecule drugs and 
their generics, the active substance of a biological agent is a collection of large protein isoforms and not a single 
molecular entity. Generating an exact replica of a protein molecule is extremely difficult if not impossible. Hence it is 
highly unlikely that the active substances will be identical between the two products — that is pharmaceutical 
equivalence is difficult to demonstrate. Moreover there are currently no analytical techniques to establish 
bioequivalence between a BS and reference biologic. Physicochemical and biological methods for characterization of 
biological agents such as monoclonal antibodies (mAb) are becoming increasingly sophisticated, but the ability to 
compare a biosimilar mAb to a reference mAb on an analytical level remains limited. Therefore compared to generic 
drugs, to illustrate the pharmacological profile of a BS necessitates a more rigorous process, and the amount of data 
required for market approval of BSs will be considerably more than for a typical generic drug application. 
Table 1 shows general agreed standard definitions for conventional generic agents, biological agents and BS based on 
terminology used by the EMA. 
At present the EMA guidelines are the only clear document detailing the requirements for market approval of 
biosimilars. The EMA guidelines advocate pre-clinical and clinical testing of BSs to demonstrate safety and efficacy 
prior to market authorization, followed by tailored pharmacovigilance plans to monitor potential immunogenicity. 
Moreover, the European guideline states that if the reference medicinal product has more than one indication, the 
efficacy and safety of a BS has to be justified, or if necessary, demonstrated separately for each of the claimed 
indications. However, the guideline also introduces the caveat of ‘extrapolation’ of data regarding efficacy and safety 
from trials designed for other indications for which a BS has not been tested. This would be only in specific 
circumstances, where the mechanism of action is the same, as was seen in the case for the hematopoetic hormones 
erythropoietin and granulocyte-colony stimulating factor. 
In the United States, the FDA has not yet issued a specific regulatory pathway. The Biologics Price Competition and 
Innovation Act (BCPI) outlined a shortened approval process for “highly similar” biological products, which enables a 
biosimilar product to be evaluated against a single, already licensed, reference biologic therapy. In February 2012, the 
FDA issued a draft guidance for the industry regarding implementation of the BPCI Act approval process for BS 
agents [6], [7], [8], [9] and [10]. Data obtained from analytical and animal studies, and from at least one clinical trial 
conducted in patients with a disease for which the biological agent is licensed, will be required to demonstrate that a BS 
product is highly similar to the reference product [2] and [10]. 
However, the draft guidance does not specify requirements for the size or duration of the required clinical trial, and the 
FDA has not yet indicated whether the trials will be required to demonstrate non-inferiority, or prove therapeutic 
equivalence, of the BS agent — therefore leaving a margin of uncertainty. 
The position of the American College of Rheumatology (ACR) has been also reported, stating that to enshrine the safety 
of patients, decisions concerning biosimilarity and interchangeability must be driven by scientifically-sound evidence. 
The ACR strongly believe that safe and effective treatments should be available to patients at the lowest possible 
cost [11]. 
Although there are no definitive rigid sets of guidelines regarding BS regulatory body approval, general unifying 
principles include prioritizing high similarity to the reference product, clinical trials demonstrating efficacy and safety, 
and a commitment to further safety profile follow-up after the drug has been approved on the market [10]. 
1.3. BSs and rheumatic disease: clinical efficacy and safety 
In a poll of US, French and German physicians in 2010, it was unanimous that efficacy compared to reference biologic 
was the most important deciding factor when considering whether to prescribe BS [12]. Although efficacy of a BS 
should be theorically equivalent to its reference product, numerous contributing factors may mean that this is not the 
case. Product attributes related to manufacturing approach (including in-process controls and product controls, 
impurities, aggregates, heterogeneity, fragments) differ between a BS and biologic. Thus, even in cases where a well-
established potency assay correlating with clinical efficacy is available, to convincingly exhibit clinically equivalence, 
human data would likely be required for BS development [5]. 
Data from physicochemical and biological characterization alone are not sufficient for BS development, and data 
coming from clinical trials are required to support similarity. The key question is, to what extent clinical trials are 
required for a BS? The goal of the clinical development program for the BS is to demonstrate no significant difference 
compared to the reference product. For that, equivalence trials of adequate sample size that are ideally double-blinded 
should be conducted. 
In August 2012 results from only one published trial was identified by searches including MEDLINE, Current Contents, 
PubMed, and amplified using a web-available search engine. Gu et al. reported a randomized, open-label, single-dose, 
two-sequence, crossover study in healthy Korean male volunteers compared with pharmacokinetics and tolerability of 
branded etanercept (25 mg) and its BS (25 mg) [13]. Twenty-five healthy Korean men were enrolled in this study and 
randomized to receive either the BS or the reference drug. In terms of safety, they reported that 52.4% of the patients 
receiving the BS and 38.1% receiving the reference drug experienced some adverse events, mainly headache, throat 
irritation, and epistaxis. The authors also described that the tested BS agent had a pharmacokinetic profile consistent 
with profiles previously reported in other etanercept pharmacokinetic studies. They concluded that, in a select group of 
Korean healthy male volunteers, branded etanercept and its BS were well tolerated and met the standard criteria for 
assuming bioequivalence as defined by Korean regulatory authorities. This data would of course need further 
confirmation and substantiation in other larger and double-blinded trials. 
1.4. Safety 
As biologicals, BSs are structurally complex proteins with significant micro-heterogeneity, produced by genetically 
modified living cells, and difficult to produce and purify. Manufacturing processes in terms of choice of cell type, 
production, purification, and formulation methods, all influence the quality, purity, biological parameters, and eventual 
clinical activity of the final product — this in turn affects efficacy and safety. 
However even if biosimilar products have the same gene sequence, vector, host cell line, culture conditions and 
purification methods as the reference protein, they can still differ substantially in some biological and clinical 
properties. Studies have indeed demonstrated differences in physical characteristics, activity, potency, safety, and 
isoform profile relative to BSs approved in other fields apart from rheumatology (e.g. epoetin alfa) [14]. Thus, the 
critical issue is to identify the clinically significant differences between BS and biologic. In brief, the question still to be 
answered is: “when are biosimilars similar enough?” 
The major issues that the EMA has highlighted remain to be addressed: regarding safety, immunogenicity, and 
extrapolation of indications [15]. When the safety of biosimilars is being assessed, identical safety parameters that were 
used for the reference agent must be applied in the development program. Nevertheless, to date, data available are few 
and fragmented, especially in terms of an evidence-based approach. Ultimately, controlled clinical trials remain the 
most reliable gold standard means of demonstrating similarity of safety profile between a biosimilar molecule and the 
reference product. 
Immunogenicity is another substantial safety concern for BSs. It refers to the ability of a protein antigen to elicit an 
immune response in a human or animal, and the subsequent production of antibodies against the protein. BSs may 
stimulate the production of anti-product antibodies, and the risk of this increases with dosing and length of time of 
treatment. This can be a particular matter of concern as it is not uncommon for treatment of chronic diseases such as 
rheumatoid arthritis to span many years. 
Several factors are known to affect a product's immunogenic potential. These can relate to the biopharmaceutical, the 
host, or a combination thereof. Immunogenicity can be induced by the active-drug substance product, but more 
commonly results from manufacturing impurities originating from the producing cell line or media components. 
Therefore the presence of impurities in biological products, structural modifications as a result of the manufacturing 
process, and/or suboptimal storage conditions, can all increase the risk of immunogenicity [16] and [17]. The anti-
product antibodies may bind to and thus attenuate or inactivate the BS, and may also result in hypersensitivity reactions 
such as allergy or serum sickness, and even anaphylaxis. The antibodies may also interfere or neutralize endogenous 
proteins, leading to unexpected effects, as happened in the cases of pure red cell aplasia induced by biosimilar 
recombinant human erythropoietins [14]. Furthermore autoimmune processes appearing after the use of biological 
agents have been described. This was apparent in the initial studies of infliximab in patients with rheumatoid arthritis 
(RA) [18]. Since then, the number and diversity of autoimmune diseases triggered by biological treatments such as anti-
tumor necrosis factor agents have risen in tandem with their increasing use, and cases of autoimmune diseases induced 
by other licensed biological agents have also been reported. With the advent of BSs there is potential for a number of 
clinical and analytical autoimmune adverse events, even different from the ones already reported from currently used 
reference biologics, which may range from asymptomatic immunological alterations to conceivably life threatening 
systemic autoimmune disease. 
Consequently postmarketing surveillance and long-term follow-up will be mandatory and emphasis on well designed 
pharmacovigilance programs following approval in order to identify rare and potentially serious events should be 
established. 
1.5. Biosimilar as a strategy to provide economically affordable treatments? 
Biologics are a successful class of therapeutic agents, but many treatments remain costly, which may limit their use. 
The potential for cost saving will unsurprisingly be of major concern for health care providers when considering BS 
versions of biological therapies if they should become available. Nevertheless, savings cannot be expected to be in the 
same order of magnitude as in the case of generics, due to high manufacturing costs, the need to perform non-clinical 
and clinical studies, and an appropriate pharmacovigilance program, as outlined above. As an example, in the UK the 
list prices of four BSs (Omnitrope®, Binocrit, Retacrit, and Ratiograstim®) compared with their respective reference 
products, are about 10–25% less in cost — a significant but not overwhelming cost saving. 
That said there is a potential for savings with the introduction of BSs that is difficult to quantify. The power of the free 
market that must not be underestimated in that competition between different manufacturers may mean the cost of BSs 
is further reduced. Also there are the indirect savings to the wider economy to be considered. Recently a systematic 
review of cost-of-illness studies in rheumatoid arthritis found a mean annual health care cost of €4170 per patient, with 
secondary costs (sick leave, lost productivity) taking total cost to €14.906 per patient per year; better control of disease 
activity will mean wider savings to the economy. 
Predicted cost savings must be carefully evaluated, however, in the absence of substantial cost savings, and lack of solid 
evidence regarding efficacy and safety, rheumatologists are likely to maintain their preference for the original biological 
agent rather than taking a chance and switching on to the BS. 
2. Conclusion 
Biosimilars pose an exciting pharmaceutical frontier in the field of Medicine, particularly in Hematology, Oncology, 
Renal Medicine and Rheumatology, where biologics are in routine use, and have had a tremendous impact on patient 
outcomes. 
It has been anticipated that by 2016, ten of the top-selling 20 drugs will be biologics and of these, three (Adalimumab, 
Rituximab, Infliximab) are monoclonal antibodies or (etanercept) a fusion protein containing antibody components 
currently widely used to treat rheumatic disease [19]. The Rheumatology field has adopted routine use of biologics 
including monoclonal antibodies, and it is therefore a desirable market for BS research. Indeed conducting a search with 
the search phrase “biosimilar” on clinicaltrials.gov revealed almost 50% of the on-going trials were related to 
Rheumatology, reflecting the propensity of expansion for biosimilar research in the Rheumatological field [3]. 
However major concerns must be addressed before a rheumatologist can routinely substitute a BS for a biological agent. 
Careful pharmacovigilance is necessary to collect clinical data with respect to short and long-term safety of BSs. In 
addition to being highly similar in structure to the reference product, the rheumatologist should expect comparable 
efficacy and safety, ideally for a reduced cost — that the patient must not be adversely affected by the change in 
prescribing practice is paramount. 
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Table 1. General agreed standard definitions for conventional generic agents, biologic agents and 
biosimilars, based on terminology used by the European Medicines Agency (EMA). 
 
 
Generic drug A chemical and therapeutic equivalent of a low-molecular-weight drug whose patent has expired 
Biological 
agents 
A medicinal product developed by means of one or more of the following biotechnology practices: 
rDNA, controlled gene expression, antibody methods 
Biosimilar A biological medicinal product referring to an existing product, submitted to regulatory authorities for 
marketing authorization by an independent application, after the time of the protection of the data has 
expired for the original existing product 
